Société Tunisienne des Maladies Respiratoires et d'Allergologie STMRA - Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

Sté Tunisienne des Maladies Respiratoires et d'Allergologie

Cercle des Bureaux - Appartement B 5-3 . 1082 Centre urbain Nord Tunis

Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

Zouhair Souissi

Bibliographie

15 octobre 2021

Soyez le premier à commenter!

Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report – medRxiv Commentary: Study: Mixing and Matching COVID-19 Booster Shots Is Effective, Safe – U.S. News Commentary on Twitter So yes, mRNA vaccines are great at generating antibodies but what does that mean? Where is the efficacy data? How come JnJ gets really great efficacy at preventing symptomatic […]

The post Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer. appeared first on Links Medicus.

Lu 542 fois